Welcome to our dedicated page for Nordicus Partners SEC filings (Ticker: NORD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Nordicus Partners's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Nordicus Partners's regulatory disclosures and financial reporting.
Nordicus Partners Corporation is a U.S.-listed biotech focused on acquiring and developing Nordic-origin drugs for diseases with unmet medical needs, initially in oral disorders and psoriasis. For the year ended March 31, 2026 it generated no revenue (versus $5,000 a year earlier) and reported a net loss attributable to the company of $4.0 million, or $0.22 per share, driven by higher R&D and corporate expenses.
Operating expenses were $4.37 million, including $1.61 million of research and development across three preclinical programs: Orocidin’s QR-01 for periodontitis, Bio-Convert’s QR-02 for oral leukoplakia, and NoviThera’s QR-04 for psoriasis. QR-01 showed efficacy in dog and rat models and QR-02 received a toxicity waiver and is moving toward GMP production, with both programs anticipating Phase IIa trials in the first half of 2027. NoviThera achieved biological proof of concept in a mouse study.
Liquidity is constrained: cash was only $20,878 at March 31, 2026 after using $4.32 million in operating cash flows, largely offset by $4.34 million raised from equity issuances. The independent auditor cited nominal revenue, recurring losses and an accumulated deficit as raising substantial doubt about Nordicus’s ability to continue as a going concern. Management is seeking additional capital and has applied to uplist its shares to the Nasdaq Capital Market.
Nordicus Partners Corporation reported a governance change involving its board of directors. On July 7, 2026, Andrew J. Ritter resigned from the Board of Directors, effective immediately, and also stepped down from the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
The company states that Mr. Ritter resigned to pursue other time-consuming business opportunities and that his resignation was not the result of any disagreement with Nordicus Partners on matters relating to its operations, policies, or practices. No financial results or major transactions are described in this report.
Nordicus Partners Corporation notified the SEC it could not file its Annual Report on Form 10-K for the fiscal year ended March 31, 2026 on time and expects to file within the 15-calendar-day extension.
The company anticipates reporting a net loss of approximately $346,731 on $0 revenues for the year. The delay reflects the need to complete accounting records and allow the independent auditor to finish the audit.
Nordicus Partners Corporation entered into a material definitive agreement related to a private stock offering, issuing 201,500 restricted shares of common stock at $2.75 per share to five private investors in March and April 2026. On June 23, 2026, the company determined to close this private offering on those terms.
The shares were issued without SEC registration, relying on exemptions under Section 4(a)(2) of the Securities Act, Rule 506(b) and (c) of Regulation D, and Regulation S for non-U.S. persons. No underwriters or agents were involved, no underwriting discounts or commissions were paid, and the securities carry transfer restrictions and a legend noting they are not registered and cannot be resold without registration or a valid exemption.
Nordicus Partners Corporation reported another pre-revenue quarter for the three months ended December 31, 2025, as it continues to build a portfolio of preclinical Nordic life sciences companies. Revenue was $0 compared with small related-party revenues in the prior year.
The company posted a net loss attributable to Nordicus of $1.23 million for the quarter and $3.95 million for the nine months, driven mainly by officer compensation, professional fees, and $1.32 million in research and development expenses over nine months. Comprehensive income for the nine months was positive $0.92 million, helped by $4.88 million in foreign currency translation gains.
At December 31, 2025, Nordicus held $189,297 in cash and total assets of $75.9 million, largely in goodwill and in-process R&D from acquisitions of Orocidin and Bio-Convert. Accumulated deficit reached $50.7 million, and management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing.
During the nine months, Nordicus raised about $3.9 million through private issuances of 1.69 million restricted shares, and subsequently raised $1.5 million from 547,036 shares at $2.75 per share. It also repurchased 57,642 shares under a limited buyback program. The portfolio now includes majority stakes in Orocidin, Bio-Convert and NoviThera, all targeting oral health and dermatology indications in preclinical stages.
Nordicus Partners Corporation reports that on November 10, 2025, its board of directors created three standing committees and adopted formal charters for each. The new committees are the Audit Committee, Compensation Committee and Nominating Committee.
The Audit Committee is composed of Kim Mücke (chair), Andrew J. Ritter and Peter Severin, and the board has designated Mr. Mücke as an “audit committee financial expert” under Securities and Exchange Commission rules. The Compensation Committee and Nominating Committee each consist of the same three directors, with different directors serving as chairs. The detailed charters for these committees are filed as exhibits to this report.
Nordicus Partners Corporation reported that in December 2025 it issued a total of 131,000 restricted shares of its common stock to ten private investors at a price of $2.75 per share. On January 5, 2026, the company decided to close this private offering on those terms. The shares were issued in a private placement and have not been registered under U.S. or other applicable securities laws, so they are subject to transfer restrictions and can only be resold under an effective registration statement or a valid exemption.
The company states that it is relying on exemptions from registration under Section 4(a)(2) of the Securities Act, Rule 506(b) and (c) of Regulation D, and Regulation S. The investors were accredited and/or had access to detailed information, there was no general solicitation, no underwriters or agents were involved, and no underwriting discounts or commissions were paid.
Nordicus Partners Corporation reported that from October through December 2025 it issued 416,000 restricted shares of its common stock in a private offering to eight investors at a price of $2.75 per share, and on December 5, 2025 determined to close the offering on these terms. The shares were sold without registration under the Securities Act of 1933, relying on exemptions including Section 4(a)(2), Rule 506(b) and (c) of Regulation D, and Regulation S. Investors were accredited and/or had access to information similar to a registration statement, acquired the stock for investment purposes, and the securities carry transfer restrictions and restrictive legends. No underwriters or agents participated, no underwriting discounts or commissions were paid, and there was no general solicitation.
Nordicus Partners Corporation (NORD) reported Q2 FY2026 results for the quarter ended September 30, 2025. The company recorded no revenue and a net loss of $1,511,474, or $0.08 per share. Operating expenses were $1,211,478, driven by officer compensation, R&D, and G&A. For the first six months, net loss totaled $2,718,360.
Liquidity remains tight. Cash was $242,155 as of September 30, 2025, after net cash used in operations of $2,188,401 in the six-month period. Financing cash inflows of $2,419,220 came from issuing 1,146,500 common shares. The company disclosed a going concern uncertainty due to nominal revenue, accumulated deficit of $49,503,208, and limited cash. Subsequent to quarter-end, it raised $618,750 via 225,000 restricted shares at $2.75 and repurchased 57,642 shares at $1.36.
Total assets were $75,882,821, including in-process R&D of $46,402,880 and goodwill of $27,696,030 tied to Orocidin A/S and Bio-Convert A/S. A fair-value decrease of $675,000 was recorded on the Mag Mile Capital investment over six months. Shares outstanding were 18,399,002 at quarter-end and 18,566,360 as of November 12, 2025.
Nordicus Partners (NORD) filed a Form 4 showing CEO Henrik Rouf sold company stock across four dates and updated his holdings. Reported sales were: 2,500 shares at $6 on 11/15/2024; 10,000 shares at $5 on 01/03/2025; 3,362 shares at $4.16 on 01/13/2025; and 26,667 shares at $2 on 08/20/2025.
Following these transactions, Mr. Rouf beneficially owns 15,973 shares. The filing notes a 1-for-10 reverse stock split effected on November 8, 2024. Of the 15,973 shares, 640 shares are held personally and 15,333 shares are held in the name of Reddington Partners LLC, for which Mr. Rouf is the sole beneficial owner.